3186 results for «602»
3186 results
Challenging and complication cases
14 Dec 2022 – From GulfPCR-GIM 2022
Among the 5 cases presented in this GulfPCR-GIM 2022 session, learn more about post aortic valve replacement complications, complex bicuspid TAVI, or primary PCI for re-implanted left main trunk post aortic root replacement, among others!
Complex left main PCI - Session with LIVE case
15 Dec 2022 – From GulfPCR-GIM 2022
Follow the discussion around the case presented LIVE in this GulfPCR-GIM 2022 session of a 68-year-old male patient with DM, HTN and hyperlipidaemia, who presented with constant exertional chest pain with class 3 angina for several weeks, and find out more about complex LM PCI.
Severe mitral and tricuspid regurgitation
15 Dec 2022 – From GulfPCR-GIM 2022
This GulfPCR-GIM 2022 session aims to illustrate the role of mitral TEER in patients with significant MR and cardiogenic shock, to demonstrate the importance of early detection, but also to show that earlier referral and treatment of patients with significant TR is essential to prevent patients...
Gulf WIN - Opportunities and challenges
15 Dec 2022 – From GulfPCR-GIM 2022
Women have the floor in this special GulfPCR-GIM 2022 session: hear from members of the Gulf WIN (Women In Intervention) to better understand the status of women interventionists in the region, explore the challenges they face, and note the differences that exist with other women cardiologists...
Optimal management of a patient with calcified lesions - Session with LIVE case
15 Dec 2022 – From GulfPCR-GIM 2022
Watch the case of an 87-year-old male patient with DM, HTN, and hyperlipidemia, who suffered ACS six weeks ago, whose culprit lesions were treated in the RCA and LCX, and who was incidentally readmitted for LAD PCI, and find out how he was treated LIVE.
Essential drugs that every interventionalist needs to know
15 Dec 2022 – From GulfPCR-GIM 2022
In this GulfPCR-GIM 2022 session, learn about the role of PCSK9 inhibitors in ACS and post-PCI patients, the role of SGLT2 receptor blockers and GLP RAs, and the role of P2Y12 inhibitors as unique post-PCI antiplatelet agents.
